Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium
Schizophr Bull
.
2024 Jan 1;50(1):5-8.
doi: 10.1093/schbul/sbad112.
Authors
Sanne Koops
1
,
Kelly Allott
2
3
,
Lieuwe de Haan
4
5
,
Eric Chen
6
,
Christy Hui
6
,
Eoin Killackey
2
3
,
Maria Long
7
8
,
Joanna Moncrieff
7
,
Iris Sommer
1
,
Anne Emilie Stürup
9
,
Lex Wunderink
1
,
Marieke Begemann
1
;
TAPER international research consortium
Collaborator
TAPER international research consortium
:
J (Julia) van der A
10
Affiliations
1
Department of Psychiatry, University Medical Center Groningen, Rijksuniversiteit Groningen, Groningen, The Netherlands.
2
Orygen, Melbourne, VIC, Australia.
3
Centre for Youth Mental Health, University of Melbourne, Melbourne, VIC, Australia.
4
Amsterdam UMC, University of Amsterdam, Department of Psychiatry, Amsterdam, The Netherlands.
5
Arkin, Institute for Mental Health, Amsterdam, The Netherlands.
6
Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong.
7
Division of Psychiatry, University College London, London, United Kingdom.
8
Department of Health Services Research and Management, City University, London, United Kingdom.
9
Copenhagen Research Center for Mental Health (CORE), Mental Health Center Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark.
10
Department of Psychiatry, University Medical Center Groningen (UMCG), Rijksuniversiteit Groningen (RUG), Groningen, Netherlands
PMID:
37625022
PMCID:
PMC10754158
DOI:
10.1093/schbul/sbad112
No abstract available
MeSH terms
Antipsychotic Agents* / pharmacology
Antipsychotic Agents* / therapeutic use
Drug Tapering
Humans
Mental Disorders* / drug therapy
Professional Practice Gaps
Substances
Antipsychotic Agents